Theranexus unveils its universal registration document for 2023

Biopharmaceutical group Theranexus, based in Lyon, France, has published its universal registration document for the 2023 financial year. The document, essential for investors and stakeholders, was made public on April 30, 2023 and is now accessible on their official website.

This filing with the Financial Markets Authority confirms the company's ongoing commitment to transparency and compliance with financial regulations. The availability of the document in the Shareholders section of the site demonstrates their openness and active communication with their investors.